Fundamentally, Anthera have today announced the successful completion of an interim analysis of its Phase 3 trial (CHABLIS-SC1) of blisibimod in patients with Systemic Lupus Erythematosus and that the study should continue to completion as planned. This is a critical milestone for the company.
In terms of , The only problem is the historical I've discovered (The black line going across the chart.)
I'm looking to take profits very quickly in case of a turn around and have a stop loss in place.
Break above the 200 and the Slow curve pattern as well as the resistance tells me this is a home run.
I took an aggressive entry and got filled at 3.29 so I've already hit a complete home run here.
Good luck traders.